MX2024008619A - Composiciones y métodos para el tratamiento de la depresión. - Google Patents
Composiciones y métodos para el tratamiento de la depresión.Info
- Publication number
- MX2024008619A MX2024008619A MX2024008619A MX2024008619A MX2024008619A MX 2024008619 A MX2024008619 A MX 2024008619A MX 2024008619 A MX2024008619 A MX 2024008619A MX 2024008619 A MX2024008619 A MX 2024008619A MX 2024008619 A MX2024008619 A MX 2024008619A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- depression
- compositions
- treatment
- patient
- Prior art date
Links
- 208000020401 Depressive disease Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 208000024714 major depressive disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/525—Tumor necrosis factor [TNF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Otolaryngology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263298060P | 2022-01-10 | 2022-01-10 | |
| PCT/IB2023/050171 WO2023131921A1 (en) | 2022-01-10 | 2023-01-09 | Compositions and methods for the treatment of depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024008619A true MX2024008619A (es) | 2024-09-25 |
Family
ID=84981673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024008619A MX2024008619A (es) | 2022-01-10 | 2023-01-09 | Composiciones y métodos para el tratamiento de la depresión. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250064779A1 (https=) |
| EP (1) | EP4463143A1 (https=) |
| JP (1) | JP2025503649A (https=) |
| KR (1) | KR20240132501A (https=) |
| CN (1) | CN118843459A (https=) |
| AU (1) | AU2023206048A1 (https=) |
| CA (1) | CA3247733A1 (https=) |
| IL (1) | IL314176A (https=) |
| MX (1) | MX2024008619A (https=) |
| WO (1) | WO2023131921A1 (https=) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19723133A1 (de) | 1997-06-03 | 1998-12-10 | Caideil M P Teoranta Tourmakea | Austragvorrichtung für Medien |
| WO2009094260A1 (en) * | 2008-01-22 | 2009-07-30 | Eli Lilly And Company | Kappa selective opioid receptor antagonist |
| JP2022548233A (ja) * | 2019-09-13 | 2022-11-17 | ヤンセン ファーマシューティカルズ,インコーポレーテッド | エスケタミンの鼻腔内投与 |
-
2023
- 2023-01-09 EP EP23700340.5A patent/EP4463143A1/en active Pending
- 2023-01-09 MX MX2024008619A patent/MX2024008619A/es unknown
- 2023-01-09 KR KR1020247026652A patent/KR20240132501A/ko active Pending
- 2023-01-09 IL IL314176A patent/IL314176A/en unknown
- 2023-01-09 WO PCT/IB2023/050171 patent/WO2023131921A1/en not_active Ceased
- 2023-01-09 CA CA3247733A patent/CA3247733A1/en active Pending
- 2023-01-09 JP JP2024541230A patent/JP2025503649A/ja active Pending
- 2023-01-09 CN CN202380026391.1A patent/CN118843459A/zh active Pending
- 2023-01-09 AU AU2023206048A patent/AU2023206048A1/en active Pending
- 2023-01-09 US US18/727,764 patent/US20250064779A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4463143A1 (en) | 2024-11-20 |
| KR20240132501A (ko) | 2024-09-03 |
| CN118843459A (zh) | 2024-10-25 |
| IL314176A (en) | 2024-09-01 |
| JP2025503649A (ja) | 2025-02-04 |
| US20250064779A1 (en) | 2025-02-27 |
| WO2023131921A1 (en) | 2023-07-13 |
| CA3247733A1 (en) | 2023-07-13 |
| AU2023206048A1 (en) | 2024-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| CL2023003259A1 (es) | Composiciones y métodos para el tratamiento de la depresión. | |
| MX2020001768A (es) | Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico. | |
| MX2020009602A (es) | Formulaciones de pulverizacion de epinefrina. | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| JOP20230157A1 (ar) | طرق مُعالجة فيروس كورونا | |
| MX2025003477A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| BR112017003552A2 (pt) | ?métodos para tratar caquexia, para tratar saciedade precoce, para aumentar o tempo de sobrevida, para melhorar a qualidade de vida e para aumentar a massa corporal total? | |
| BR112023002668A2 (pt) | Composições e métodos para tratar cânceres egfr positivos | |
| CO2022010592A2 (es) | Métodos de tratamiento de la esplenomegalia | |
| MX2023000164A (es) | Métodos y composiciones para tratar la hemofilia. | |
| CO2022014199A2 (es) | Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus, incluyendo covid-19 | |
| MX2024010980A (es) | Formas polimórficas de aticaprant para usar en el tratamiento del trastorno depresivo mayor | |
| MX2022001450A (es) | Metodo de tratamiento del cancer. | |
| MX2024008619A (es) | Composiciones y métodos para el tratamiento de la depresión. | |
| BR112023024701A2 (pt) | Métodos de tratamento de doenças do fígado | |
| EA200501803A1 (ru) | Сочетание аналептика модафинила и антидепрессанта для лечения депрессии | |
| EA202091653A1 (ru) | Миноциклин для лечения воспалительных заболеваний кожи | |
| CL2023002236A1 (es) | Métodos para tratar la amiloidosis primaria | |
| MX2024015839A (es) | Composiciones y usos de psilocibina y psilocina | |
| MX2022000082A (es) | Composiciones terapeuticas y metodos para tratar canceres. | |
| CO2023014650A2 (es) | Dosificación y administración de l-asparaginasa recombinante | |
| BR112022025901A2 (pt) | Composições e métodos para tratar transtorno obsessivo-compulsivo | |
| BR112022026070A2 (pt) | Terapia combinada de verapamil e mometasona para o tratamento de rinosinosinusite crônica | |
| BR112023022273A2 (pt) | Agrupamentos de ouro, composições e métodos para tratamento de depressão |